Advertisement

Reactions Weekly

, Volume 1739, Issue 1, pp 2–2 | Cite as

US FDA update on nitrosamine impurities investigation

Comment
  • 20 Downloads

Reference

  1. Gottlieb S, et al. Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the FDA's ongoing investigation into valsartan and ARB class impurities and the agency's steps to address the root causes of the safety issues. Internet Document : 25 Jan 2019. Available from: URL: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629796.htm

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations